MariMed Inc. (MRMD) discloses director RSU award settled in stock

Rhea-AI Filing Summary

MariMed Inc. director David R. Allen reported the conversion of restricted stock units into 176,389 shares of common stock on December 15, 2025. The transaction is shown as an acquisition at a price of $0, reflecting the settlement of equity awards rather than a cash purchase.

After this transaction, Allen directly beneficially owns 476,144 shares of MariMed common stock. The RSUs converted on a one-for-one basis, were granted on December 5, 2025, and vested in full on December 15, 2025. They were granted in lieu of cash as payment for a portion of his fees for serving on MariMed’s board of directors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allen David R

(Last) (First) (Middle)

C/O MARIMED INC.

10 OCEANA WAY

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	12/15/2025		M		176,389	A	$0(1)	476,144	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSU)	(1)	12/15/2025		M			176,389	(2)	(2)	Common Stock, par value $.001 per share	176,389	$0	0	D

Explanation of Responses:

1. RSUs convert to shares of common stock on a one-for-one basis.

2. These RSUs were granted on December 5, 2025 and vested in full on December 15, 2025 in accordance with the terms of an award agreement between the Issuer and the Reporting Person.

Remarks:

The RSUs were granted in lieu of cash as payment for a portion of the Reporting Person's fees for serving on the Issuer's Board of Directors.

	/s/ David R. Allen	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MariMed (MRMD) disclose in this filing?

The filing reports that director David R. Allen converted restricted stock units into 176,389 shares of MariMed common stock on December 15, 2025, at a stated price of $0.

Who is the reporting person in the MariMed (MRMD) Form 4 and what is their role?

The reporting person is David R. Allen, who is identified as a director of MariMed Inc. The form is filed by one reporting person.

How many MariMed (MRMD) shares does the director own after the reported transaction?

Following the conversion of RSUs, David R. Allen beneficially owns 476,144 shares of MariMed common stock in direct ownership.

What are RSUs and how did they convert in this MariMed (MRMD) transaction?

The filing states that the RSUs convert to shares of common stock on a one-for-one basis. In this case, 176,389 RSUs converted into 176,389 shares of common stock.

When were the RSUs granted and when did they vest for the MariMed (MRMD) director?

The RSUs were granted on December 5, 2025 and vested in full on December 15, 2025, according to the terms of an award agreement between MariMed and the reporting person.

Why were the RSUs granted to the MariMed (MRMD) director instead of cash?

The filing explains that the RSUs were granted in lieu of cash as payment for a portion of the reporting person’s fees for serving on MariMed’s Board of Directors.